



Supplementary Figure 1



Supplementary Figure 1

Effect of CEACAM6 on adenovirus infection. **(A)** CEACAM6 expression in stable CEACAM6-overexpressing PaTu8988t cells after transfection with control siRNAs or CEACAM6-specific siRNAs and withdrawal of Zinc Sulphate from the medium for 3 weeks. **(B)** Ad-GFP expression in PaTu8988t-Hyg cells and PaTu8988t-CEACAM6 cells after down-regulation of CEACAM6 by siRNA or withdrawal of CEACAM6 expression-inducer Zinc Sulphate. The GFP expression was detected by FACS at 24 hours after infection with Ad-CMV-GFP adenovirus. The experiments were triplicated. ** $p < 0.01$. **(C)** Cytotoxicity of oncolytic adenovirus in PaTu8988t-Hyg cells and PaTu8988t-CEACAM6 cells after down-regulation of CEACAM6 by siRNA or withdrawal of the CEACAM6 expression-inducer Zinc Sulphate. The experiments were duplicated. ** $p < 0.01$.


Supplementary Figure 2



Supplementary Figure 2

Effect of CEACAM6 on adenovirus infection. **(A)** CEACAM6 expression measured by Western blotting in CEACAM6-siRNA knockdown Suit-2 cells after transfection with a CEACAM6-expressing plasmid or control plasmid. 1×10^5 of Suit-2 cells were transfected with CEACAM6-specific siRNA first, and 48 hours later the cells were transfected with CEACAM6-expressing plasmid pML1 or control plasmid. The cells were harvested for Western blot at 24 hours and 48 hours. **(B)** Adenovirus infectivity assayed by Ad-CMV-GFP virus in Suit-2 cells manipulated by siRNA and CEACAM6-expressing plasmid. **(C)** CEACAM6 expression in Suit-2 cells after transfection of CEACAM6-specific siRNA and control siRNAs over a time course. **(D)** Adenovirus infectivity assayed by Ad-CMV-GFP virus in Suit-2 cells after down-regulation of CEACAM6 by siRNA at different time points. **(E)** Adenovirus cytotoxicity in Suit-2 cells after down-regulation of CEACAM6 by siRNA at different time points. The GFP expression (**B** and **D**) was detected by FACAS at 24 hours after infection with Ad-CMV-GFP adenovirus. All experiments were duplicated. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.


Supplementary Figure3



Supplementary Figure 3

CEACAM6 does not affect CAR expression. **(A)** FACS analysis showing the expression of CAR in stable clones PaTu8988t-Hyg and PaTu8988t-CEACAM6. **(B)** FACS analysis showing the expression of CAR in control and the CEACAM6-specific SMART™ pool siRNA-treated Suit-2 cells.

Supplementary Figure 4



Supplementary Figure 4

The expression of integrins in stable clones PaTu8988t-Hyg and PaTu8988t-CEACAM6 and in control and CEACAM6-specific SMART™ pool siRNA-treated Suit-2 cells.